nodes	percent_of_prediction	percent_of_DWPC	metapath
Phylloquinone—Scleroderma—Bleomycin—lymphatic system cancer	0.179	0.179	CcSEcCtD
Phylloquinone—Cyanosis—Teniposide—lymphatic system cancer	0.0531	0.0531	CcSEcCtD
Phylloquinone—Phlebitis—Teniposide—lymphatic system cancer	0.0317	0.0317	CcSEcCtD
Phylloquinone—Phlebitis—Fludarabine—lymphatic system cancer	0.0279	0.0279	CcSEcCtD
Phylloquinone—Necrosis—Carmustine—lymphatic system cancer	0.027	0.027	CcSEcCtD
Phylloquinone—Injection site pain—Carmustine—lymphatic system cancer	0.0259	0.0259	CcSEcCtD
Phylloquinone—Necrosis—Mitoxantrone—lymphatic system cancer	0.0251	0.0251	CcSEcCtD
Phylloquinone—Injection site reaction—Carmustine—lymphatic system cancer	0.021	0.021	CcSEcCtD
Phylloquinone—Phlebitis—Bleomycin—lymphatic system cancer	0.0204	0.0204	CcSEcCtD
Phylloquinone—Sweating increased—Fludarabine—lymphatic system cancer	0.0202	0.0202	CcSEcCtD
Phylloquinone—Sweating—Teniposide—lymphatic system cancer	0.0202	0.0202	CcSEcCtD
Phylloquinone—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.0182	0.0182	CcSEcCtD
Phylloquinone—Phlebitis—Carmustine—lymphatic system cancer	0.0178	0.0178	CcSEcCtD
Phylloquinone—Flushing—Teniposide—lymphatic system cancer	0.0175	0.0175	CcSEcCtD
Phylloquinone—Swelling—Carmustine—lymphatic system cancer	0.0174	0.0174	CcSEcCtD
Phylloquinone—Phlebitis—Mitoxantrone—lymphatic system cancer	0.0166	0.0166	CcSEcCtD
Phylloquinone—Swelling—Mitoxantrone—lymphatic system cancer	0.0162	0.0162	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Mitoxantrone—lymphatic system cancer	0.0148	0.0148	CcSEcCtD
Phylloquinone—Cyanosis—Methotrexate—lymphatic system cancer	0.0138	0.0138	CcSEcCtD
Phylloquinone—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.0134	0.0134	CcSEcCtD
Phylloquinone—Hyperhidrosis—Teniposide—lymphatic system cancer	0.013	0.013	CcSEcCtD
Phylloquinone—Hypotension—Teniposide—lymphatic system cancer	0.0125	0.0125	CcSEcCtD
Phylloquinone—Necrosis—Methotrexate—lymphatic system cancer	0.0125	0.0125	CcSEcCtD
Phylloquinone—Sweating increased—Mitoxantrone—lymphatic system cancer	0.012	0.012	CcSEcCtD
Phylloquinone—Dyspnoea—Teniposide—lymphatic system cancer	0.012	0.012	CcSEcCtD
Phylloquinone—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.0118	0.0118	CcSEcCtD
Phylloquinone—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.0114	0.0114	CcSEcCtD
Phylloquinone—Flushing—Bleomycin—lymphatic system cancer	0.0113	0.0113	CcSEcCtD
Phylloquinone—Sweating—Vincristine—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Phylloquinone—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.0108	0.0108	CcSEcCtD
Phylloquinone—Erythema—Bleomycin—lymphatic system cancer	0.0106	0.0106	CcSEcCtD
Phylloquinone—Sweating—Mitoxantrone—lymphatic system cancer	0.0105	0.0105	CcSEcCtD
Phylloquinone—Dyspnoea—Fludarabine—lymphatic system cancer	0.0105	0.0105	CcSEcCtD
Phylloquinone—Inflammation—Methotrexate—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Phylloquinone—Pain—Fludarabine—lymphatic system cancer	0.0101	0.0101	CcSEcCtD
Phylloquinone—Hypersensitivity—Teniposide—lymphatic system cancer	0.00989	0.00989	CcSEcCtD
Phylloquinone—Flushing—Carmustine—lymphatic system cancer	0.00986	0.00986	CcSEcCtD
Phylloquinone—Erythema—Carmustine—lymphatic system cancer	0.00925	0.00925	CcSEcCtD
Phylloquinone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00869	0.00869	CcSEcCtD
Phylloquinone—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00865	0.00865	CcSEcCtD
Phylloquinone—Erythema—Mitoxantrone—lymphatic system cancer	0.0086	0.0086	CcSEcCtD
Phylloquinone—Hypotension—Bleomycin—lymphatic system cancer	0.00808	0.00808	CcSEcCtD
Phylloquinone—Dyspnoea—Bleomycin—lymphatic system cancer	0.00771	0.00771	CcSEcCtD
Phylloquinone—Pain—Bleomycin—lymphatic system cancer	0.0074	0.0074	CcSEcCtD
Phylloquinone—Anaphylactoid reaction—Methotrexate—lymphatic system cancer	0.00735	0.00735	CcSEcCtD
Phylloquinone—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00721	0.00721	CcSEcCtD
Phylloquinone—Hypotension—Carmustine—lymphatic system cancer	0.00705	0.00705	CcSEcCtD
Phylloquinone—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00702	0.00702	CcSEcCtD
Phylloquinone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00697	0.00697	CcSEcCtD
Phylloquinone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00678	0.00678	CcSEcCtD
Phylloquinone—Hypotension—Vincristine—lymphatic system cancer	0.00673	0.00673	CcSEcCtD
Phylloquinone—Dyspnoea—Carmustine—lymphatic system cancer	0.00673	0.00673	CcSEcCtD
Phylloquinone—Hypotension—Mitoxantrone—lymphatic system cancer	0.00656	0.00656	CcSEcCtD
Phylloquinone—Pain—Carmustine—lymphatic system cancer	0.00646	0.00646	CcSEcCtD
Phylloquinone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00637	0.00637	CcSEcCtD
Phylloquinone—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00626	0.00626	CcSEcCtD
Phylloquinone—Pain—Vincristine—lymphatic system cancer	0.00616	0.00616	CcSEcCtD
Phylloquinone—Pain—Mitoxantrone—lymphatic system cancer	0.006	0.006	CcSEcCtD
Phylloquinone—Hypersensitivity—Carmustine—lymphatic system cancer	0.00556	0.00556	CcSEcCtD
Phylloquinone—Hypersensitivity—Vincristine—lymphatic system cancer	0.00531	0.00531	CcSEcCtD
Phylloquinone—Sweating—Methotrexate—lymphatic system cancer	0.00526	0.00526	CcSEcCtD
Phylloquinone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00517	0.00517	CcSEcCtD
Phylloquinone—Dizziness—Carmustine—lymphatic system cancer	0.00499	0.00499	CcSEcCtD
Phylloquinone—Dizziness—Vincristine—lymphatic system cancer	0.00477	0.00477	CcSEcCtD
Phylloquinone—Immune system disorder—Methotrexate—lymphatic system cancer	0.00445	0.00445	CcSEcCtD
Phylloquinone—Erythema—Methotrexate—lymphatic system cancer	0.00428	0.00428	CcSEcCtD
Phylloquinone—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.0035	0.0035	CcSEcCtD
Phylloquinone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Phylloquinone—Hypotension—Methotrexate—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Phylloquinone—Dyspnoea—Methotrexate—lymphatic system cancer	0.00312	0.00312	CcSEcCtD
Phylloquinone—Pain—Methotrexate—lymphatic system cancer	0.00299	0.00299	CcSEcCtD
Phylloquinone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Phylloquinone—Dizziness—Methotrexate—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
